The clinical impact of continued smoking in patients with breast and other hormone-dependent cancer: A systematic literature review.

Breast cancer Endometrial cancer Hormones Ovarian cancer Prostate cancer Smoking cessation Survival Systematic review

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 16 09 2022
revised: 07 02 2023
accepted: 17 02 2023
medline: 3 4 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

We conducted a systematic review of studies that investigated whether quitting smoking at or around diagnosis improves survival of patients with hormone-dependent cancers (HDC). Nine studies published in 2013-2022 were included. Studies were very diverse in terms of design, definition of quitters and continued smokers, and prevalence of prognostic factors other than smoking cessation (e.g. patients' demographics, tumour characteristic, and treatments). For breast, ovarian, and endometrial cancer, all included studies found that quitters had better overall, disease specific, and disease-free survival than continued smokers. For prostate cancer, there was no evidence of an association of smoking cessation with improved survival. This literature review provided suggestive evidence that female smokers diagnosed with cancer of the breast, ovary, or endometrium may improve their chances of surviving by stopping smoking. Smoking cessation counselling should become part of standard oncological care for these patients and integrated into breast cancer screening programs.

Identifiants

pubmed: 36805551
pii: S1040-8428(23)00039-2
doi: 10.1016/j.critrevonc.2023.103951
pii:
doi:

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103951

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

Marco Del Riccio (M)

Postgraduate School in Hygiene and Preventive Medicine, University of Florence, Florence, Italy.

Virginia Vettori (V)

Department of Health Sciences, University of Florence, Florence, Italy.

Sara Raimondi (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Chiara Lorini (C)

Department of Health Sciences, University of Florence, Florence, Italy.

Giovanna Masala (G)

Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Maria Sofia Cattaruzza (MS)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Luca Mazzarella (L)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Early Drug Development, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Guglielmo Bonaccorsi (G)

Department of Health Sciences, University of Florence, Florence, Italy.

Marianna Masiero (M)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Applied Research Division of Cognitive and Psychological Science, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Benedetta Bendinelli (B)

Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Giuseppe Curigliano (G)

Department of Early Drug Development, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Gabriella Pravettoni (G)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Applied Research Division of Cognitive and Psychological Science, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Elisa Pastore (E)

Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Sara Gandini (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy. Electronic address: sara.gandini@ieo.it.

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH